Reversing FXa inhibitor activity in patients with acute major bleeding

Monday, May 22nd, 2023 | 11:00 AM - 12:00 PM CT

Every day, patients are hospitalized with a factor Xa (FXa) inhibitor-related acute major bleed. For those patients, every moment matters. Uncover the latest information on managing patients with FXa inhibitor-related acute major bleeding in this live discussion.

Learning Points:
  • The burden of life-threatening bleeds related to FXa Inhibitors
  • The rationale behind the reversal of anti-FXa activity
  • Clinical trials evaluating the efficacy and safety of FXa inhibitor reversal
  • Real world studies evaluating FXa inhibitor reversals 


Paul Dobesh

Paul P. Dobesh, Pharm.D., FACC, FAHA, FCCP, BCPS, BCCP

Professor of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center